WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

Search

Hims & Hers Health Inc

Cerrado

SectorConsumo defensivo

31.15 0.48

Resumen

Variación precio

24h

Actual

Mínimo

28.94

Máximo

31.21

Métricas clave

By Trading Economics

Ingresos

-50M

26M

Ventas

80M

481M

P/B

Media del Sector

54.722

44.466

BPA

0.227

Margen de beneficio

5.409

Empleados

1,637

EBITDA

-8.2M

19M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+49.76% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-4.7B

6.5B

Apertura anterior

30.67

Cierre anterior

31.15

Noticias sobre sentimiento de mercado

By Acuity

18%

82%

9 / 152 Clasificación en Consumer defensive

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Hims & Hers Health Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 abr 2025, 23:15 UTC

Principales Movimientos del Mercado

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25 feb 2025, 15:33 UTC

Principales Movimientos del Mercado

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18 nov 2024, 19:07 UTC

Principales Movimientos del Mercado

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14 oct 2024, 15:02 UTC

Principales Movimientos del Mercado

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

3 oct 2024, 11:28 UTC

Principales Movimientos del Mercado

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

2 abr 2025, 16:53 UTC

Principales Noticias

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19 mar 2025, 15:54 UTC

Principales Noticias

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21 feb 2025, 23:20 UTC

Ganancias

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10 feb 2025, 12:00 UTC

Principales Noticias

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19 dic 2024, 17:16 UTC

Principales Noticias

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19 dic 2024, 15:14 UTC

Principales Noticias

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19 dic 2024, 15:02 UTC

Principales Noticias

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16 dic 2024, 13:47 UTC

Principales Noticias

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16 dic 2024, 07:00 UTC

Principales Noticias

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3 oct 2024, 14:45 UTC

Principales Noticias

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3 oct 2024, 13:12 UTC

Principales Noticias

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 oct 2024, 11:45 UTC

Principales Noticias

Update: Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 oct 2024, 10:14 UTC

Principales Noticias

Update: Eli Lilly's Weight-Loss Drugs No Longer In Shortage. It's Bad News for These Stocks. -- Barrons.com

2 ago 2024, 17:52 UTC

Adquisiciones, fusiones, absorciones

Hims & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky -- Barrons.com

26 jun 2024, 11:00 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

24 may 2024, 20:37 UTC

Ganancias

The Score: Target, Nvidia, Live Nation and More Stocks That Defined the Week -- WSJ

Comparación entre iguales

Cambio de precio

Hims & Hers Health Inc Esperado

Precio Objetivo

By TipRanks

49.76% repunte

Estimación a 12 meses

Media 46.5 USD  49.76%

Máximo 85 USD

Mínimo 21 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hims & Hers Health Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

13 ratings

5

Comprar

6

Mantener

2

Vender

Puntuación técnica

By Trading Central

31.0237 / 31.88Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

9 / 152 Clasificación en Consumo defensivo

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.